We are live on ! Find out more
DRMAW icon

Dermata Therapeutics Warrant
DRMAW

4 hedge funds and large institutions have $38K invested in Dermata Therapeutics Warrant in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less funds holding

Funds holding: 6 → 4 (-2)

67% less capital invested

Capital invested by funds: $115K → $38K (-$77K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$3K
2
UBS Group
UBS Group
Switzerland
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
1
Empery Asset Management
New York
$19K – – –
WAM
2
Warberg Asset Management
Illinois
$11K – – –
BFM
3
Boothbay Fund Management
New York
$8K – – –
AC
4
Armistice Capital
New York
$36 – – –
VF
5
Virtu Financial
New York
– -$3K -18,171 Closed
UBS Group
6
UBS Group
Switzerland
– -$1K -3,267 Closed

DRMAW Hedge Fund Activity: Q2 2022 in Review

4 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q2 2022, worth a combined $38K — down 67% from $115K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of DRMAW and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Virtu Financial, exiting entirely with an estimated $3K sold.

  • 4 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q2 2022, down from 6 in Q1 2022.
  • Funds reported $38K of Dermata Therapeutics Warrant stock for Q2 2022, down 67% quarter-over-quarter.
  • 0 funds opened new Dermata Therapeutics Warrant positions in Q2 2022 and 2 closed out, a net change of -2 holders.
  • The largest Dermata Therapeutics Warrant seller in Q2 2022 was Virtu Financial, an estimated $3K sold.

Based on aggregated 13F filings for Q2 2022.